Roberta DeBiasi, MD
Faculty, Children's National Medical Center,

Roberta Lynn DeBiasi, MD, recently joined Children’s National Medical Center and the George Washington University School of Medicine and Health Sciences as an associate professor of Pediatrics in the Division of Pediatric Infectious Diseases, and an investigator at Children’s Research Institute in the Center for Cancer and Immunology.

After graduating Phi Beta Kappa from Boston University, she received her Doctorate in Medicine at the University of Virginia School of Medicine, and then completed her internship and residency in Pediatrics at the University of California, Davis Medical Center. She completed a fellowship in Pediatric Infectious Diseases at the University of Colorado and subsequently joined the faculty there. After ten years in Colorado, she relocated to the DC area in 2006.

Dr. DeBiasi has a multitude of research interests, including mechanisms of viral pathogenesis and the development of new treatments for serious viral infections. She is the author of original research, review articles, and book chapters, spanning a broad list of topics including infections of the heart and central nervous system, as well as pediatric immunization. For her research contributions, she was awarded the Infectious Diseases Society of America Young Investigator Award in 2000 and subsequently, a five year grant from the NIH National Institute of Allergy and Infectious Disease.

Her basic science research focuses on the pathogenesis and delineation of key signaling pathways in viral myocarditis, including virus-induced apoptosis. Using genomic and proteomic approaches in an in-vitro and in-vivo animal model of viral myocarditis, she is working to discover novel antiviral strategies for treatment of severe viral infections, including myocarditis, encephalitis, and hepatitis. Her clinical expertise and clinical research interests include infections of the central nervous system, viral myocarditis, and emerging infectious diseases. She is an active member of the NIAID Collaborative Antiviral Study Group.




Follow on: